Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is experiencing strong growth in new patient starts and an increase in pharmacy adds. They also have a strong sales force expansion and product pipeline, with the potential for FDA approval and launch of their Mint patch pump in 2026, which should help boost revenues and margins. Despite recent headwinds, the company has a solid track record of beating and raising guidance and offers a favorable risk-reward at current levels.

Bears say

Beta Bionics is facing strong competition from both devices, such as Medtronic, Tandem, Insulet, and Sequel, and therapeutics, such as GLP-1s, creating significant pressure on market share and profitability. Additionally, potential risks associated with clinical and regulatory processes for their future products, specifically the Mint patch pump and Bihormonal offerings, could further hinder their ability to gain market traction. These factors, combined with potential market headwinds from CMS proposals and a recent WL from the FDA, may result in downward pressure on BBNX's stock value and delay their commercialization timeline.

BBNX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 10 analysts, BBNX has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.